Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total value of $416,500.00. Following the sale, the insider now owns 215,000 shares in the company, valued at $17,909,500. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) opened at $73.93 on Thursday. Spark Therapeutics, Inc. has a 52 week low of $45.69 and a 52 week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative return on equity of 75.29% and a negative net margin of 1,090.11%. The firm’s quarterly revenue was up 45.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.07) EPS. equities analysts predict that Spark Therapeutics, Inc. will post -7.56 EPS for the current fiscal year.
WARNING: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/09/spark-therapeutics-inc-once-insider-sells-416500-00-in-stock.html.
Several brokerages have recently weighed in on ONCE. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a research report on Friday, October 6th. BMO Capital Markets set a $89.00 price objective on Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 10th. Cowen and Company reissued a “buy” rating and set a $95.00 price objective on shares of Spark Therapeutics in a report on Tuesday, October 10th. Raymond James Financial, Inc. began coverage on Spark Therapeutics in a report on Thursday, October 12th. They set an “outperform” rating and a $96.00 price objective for the company. Finally, Barclays PLC boosted their price objective on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the company. Spark Therapeutics has a consensus rating of “Buy” and a consensus target price of $90.36.
Several large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Spark Therapeutics by 167.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,191 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 2,000 shares during the period. EAM Investors LLC purchased a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $2,447,000. Chartwell Investment Partners LLC purchased a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $1,887,000. Ameriprise Financial Inc. boosted its stake in shares of Spark Therapeutics by 6.0% during the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock valued at $18,489,000 after purchasing an additional 11,785 shares during the period. Finally, SG Americas Securities LLC boosted its stake in shares of Spark Therapeutics by 399.6% during the third quarter. SG Americas Securities LLC now owns 17,113 shares of the biotechnology company’s stock valued at $1,526,000 after purchasing an additional 13,688 shares during the period. 77.30% of the stock is owned by hedge funds and other institutional investors.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.